ATE285755T1 - Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung - Google Patents

Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung

Info

Publication number
ATE285755T1
ATE285755T1 AT00959327T AT00959327T ATE285755T1 AT E285755 T1 ATE285755 T1 AT E285755T1 AT 00959327 T AT00959327 T AT 00959327T AT 00959327 T AT00959327 T AT 00959327T AT E285755 T1 ATE285755 T1 AT E285755T1
Authority
AT
Austria
Prior art keywords
spray drying
porous particles
large porous
particles available
particles
Prior art date
Application number
AT00959327T
Other languages
German (de)
English (en)
Inventor
Michael M Lipp
Richard P Batycky
Giovanni Caponetti
Original Assignee
Advanced Inhalation Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Res Inc filed Critical Advanced Inhalation Res Inc
Application granted granted Critical
Publication of ATE285755T1 publication Critical patent/ATE285755T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00959327T 1999-08-25 2000-08-23 Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung ATE285755T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15066299P 1999-08-25 1999-08-25
PCT/US2000/023118 WO2001013892A2 (en) 1999-08-25 2000-08-23 Large porous particles by spray-drying

Publications (1)

Publication Number Publication Date
ATE285755T1 true ATE285755T1 (de) 2005-01-15

Family

ID=22535487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959327T ATE285755T1 (de) 1999-08-25 2000-08-23 Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung

Country Status (7)

Country Link
EP (1) EP1210069B1 (enExample)
JP (1) JP2003507411A (enExample)
AT (1) ATE285755T1 (enExample)
AU (1) AU768299B2 (enExample)
CA (1) CA2383491A1 (enExample)
DE (1) DE60017152D1 (enExample)
WO (1) WO2001013892A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1280520E (pt) * 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
JP2004528339A (ja) * 2001-04-26 2004-09-16 ネクター セラピューティクス 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
CA2465779A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
AU2003287132B2 (en) * 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
JP2012522009A (ja) * 2009-03-26 2012-09-20 パルマトリックス,インコーポレイテッド 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
CA2809666C (en) * 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
ES2710537T3 (es) * 2010-09-29 2019-04-25 Pulmatrix Operating Co Inc Polvos secos catiónicos
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
AU2015213678C1 (en) 2014-02-10 2019-03-21 Respivant Sciences Gmbh Mast cell stabilizers treatment for systemic disorders
EP3104854B1 (en) 2014-02-10 2020-04-08 Respivant Sciences GmbH Mast cell stabilizers for lung disease treatment
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
CA3133804A1 (en) * 2019-03-22 2020-10-01 Mannkind Corporation Inhalable dry powders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
WO1997026863A1 (de) * 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
EP0954282B1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation

Also Published As

Publication number Publication date
EP1210069A2 (en) 2002-06-05
EP1210069B1 (en) 2004-12-29
AU768299B2 (en) 2003-12-04
DE60017152D1 (de) 2005-02-03
WO2001013892A3 (en) 2001-06-21
WO2001013892A2 (en) 2001-03-01
AU7066600A (en) 2001-03-19
JP2003507411A (ja) 2003-02-25
CA2383491A1 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
ATE285755T1 (de) Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
DK1210068T3 (da) Anvendelse af simple aminosyrer til dannelse af poröse partikler
MY129941A (en) Novel dihydro-isoquinoline derivatives
JP2003507412A5 (enExample)
CA2086434A1 (en) Quinuclidine derivatives
CA2280447A1 (en) Pyrrolo¬1,2-a|pyrazine derivatives as 5ht1a ligands
BR9813477A (pt) Derivados de benzamidina
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
CA2181175A1 (en) Dihydro Pyrazolopyrroles
DE69518656D1 (de) Antimikrobielle zusammensetzung
CA2260213A1 (en) Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
JP2003507411A5 (enExample)
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
CA2415354A1 (en) Phospholipid derivatives of valproic acid and mixtures thereof
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
ES2117426T3 (es) Forma cristalina de la sal anhidra compuesta de los acidos 7-((1a,5a,6a)-6-amino-3-azabiciclo(3.1.0.)hex-3-il)-6-fluoro-1-(2,4-difluorofenil)-1,4-dihidro-4-oxo-1,8-naftiridina-3-carboxilico y metanosulfonico.
CA2264005A1 (en) Piperazino derivatives as neurokinin antagonists
ATE242242T1 (de) Derivate von imidazo(1,2-a)pyridin zur behandlung von gastrointestinalen krankheiten
PT1427417E (pt) Derivados de 6, 7-di-hidroxitetra-hidroisoquinolina substituída em 3 para utilização como agentes antibacterianos
SE9902387D0 (sv) New pharmaceutically active compounds
WO2000002877A3 (en) New pharmaceutically active compounds
US20050025738A1 (en) Liquid air freshener and water treatment for use with humidifiers
BG106329A (en) Taste masking of oral quinolone liquid preparations using ion exchange resins
DE60213819D1 (de) Pharmazeutische Zubereitung enthaltend poröse sphärische kohlenstoffhaltige Teilchen und deren Verwendung zur Behandlung von Leber- und Nierenerkrankungen
MX9602657A (es) Derivados de acido fosfonico que contienen un anillo de triazol como herbicidas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties